Castle D

Centre for Mental Health Services Innovation, University of Tasmania, Hobart, TAS, Australia.

8 papers · ORCID

ArticlePsilocybin

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial.

Meikle S, Carter O, Liknaitzky P +6

Europe PMC2025
ArticlePsilocybin

A proof-of concept randomized controlled trial to show that the antidepressant effect of psilocybin does not require a psychedelic experience: study protocol

Husain M, Blumberger D, Castle D +4

Europe PMC2023
ArticlePsilocybin

Default Mode Network Modulation by Psychedelics: A Systematic Review.

Gattuso JJ, Perkins D, Ruffell S +11

Europe PMC2023
ArticleKetamine

A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs.

Solmi M, Chen C, Daure C +14

Europe PMC2022
ArticlePsilocybin

A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.

Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F +14

Europe PMC2022
ArticlePsilocybin

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.

Rosenblat JD, Husain MI, Lee Y +18

Europe PMC2023
ArticlePsilocybin

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.

Ling S, Ceban F, Lui LMW +12

Europe PMC2022
ArticlePsilocybin

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.

Perkins D, Sarris J, Rossell S +17

Europe PMC2021